return to news
  1. Anthem Biosciences IPO opens for subscription: Check price band, lot size and key points to know

Market News

Anthem Biosciences IPO opens for subscription: Check price band, lot size and key points to know

Upstox

3 min read | Updated on July 14, 2025, 10:00 IST

Twitter Page
Linkedin Page
Whatsapp Page

SUMMARY

Anthem Biosciences IPO is looking to raise ₹3,395 crore via the offer for sale of 5.96 crore shares. The company will not get any issue proceeds as there is no fresh issuance of shares. The money generated will go to selling shareholders.

Anthem Biosciences produces and sells complex specialised fermentation-based active pharmaceutical ingredients. | Image: Anthembio.com

Anthem Biosciences produces and sells complex specialised fermentation-based active pharmaceutical ingredients. | Image: Anthembio.com

Anthem Biosciences IPO: The initial public offering of Anthem Biosciences Ltd opened for public subscription on Monday, July 14. The initial share sale, with a price band of ₹540 to ₹570 per share, will end on July 16.

The issue is looking to raise ₹3,395 crore via the offer for sale of 5.96 crore shares. The company will not get any IPO proceeds as there is no fresh issuance of shares. The money generated will go to selling shareholders.

On Friday, Anthem Biosciences collected ₹1,016 crore in the anchor round from investors, including Abu Dhabi Investment Authority, Eastspring Investments, Government Pension Fund Global, Amundi Funds, PineBridge Global Funds, Societe Generale, HDFC Mutual Fund (MF), Axis MF, UTI MF, Quant MF, and ICICI Prudential MF.

The firm allocated 1.78 crore shares to 60 funds at ₹570 per unit at the upper price band.

Anthem Biosciences IPO lot size

Investors can apply for at least one lot, consisting of 26 shares. The company has reserved 50% of the shares for qualified institutional buyers, 35% for retail investors and the pending 15% for non-institutional investors.

Anthem Biosciences IPO key dates: Allotment and listing details

Anthem Biosciences IPO allotment is likely to be finalised on July 17. The company's shares will debut on the NSE and the BSE on July 21.

Anthem Biosciences IPO GMP

According to investorgain.com, Anthem Biosciences' unlisted shares are trading at ₹670, reflecting a grey market premium (GMP) of 17.54% or ₹100 over the issue price of ₹570.
Disclaimer: Grey Market Premium, or GMP, is an unofficial indicator of market sentiment toward an IPO. It is not regulated by the stock exchanges or SEBI. Upstox neither supports nor encourages grey market trading. Investors are advised to conduct their own research or consult an expert before making any investment decisions.

About Anthem Biosciences

Anthem is a Contract Research, Development and Manufacturing Organisation (CRDMO) with operations spanning across drug discovery, development and manufacturing.

It produces and sells complex specialised fermentation-based APIs (Active Pharmaceutical Ingredients), including enzymes, probiotics, peptides, vitamin analogues, nutritional actives, and biosimilars.

The company's listed peers are Divi's Laboratories, Sai Life Sciences Ltd, Syngene International, and Suven Life Sciences.

Citigroup Global Markets India, JM Financial, Nomura Financial Advisory and Securities (India) and JP Morgan India are the IPO's book-running lead managers, while KFin Technologies is the registrar.

To learn more about IPOs, their listings, schedules, and upcoming IPOs, visit our page.
SIP
Consistency beats timing.
promotion image

About The Author

Upstox
Upstox News Desk is a team of journalists who passionately cover stock markets, economy, commodities, latest business trends, and personal finance.

Next Story